[HTML][HTML] Mechanisms of resistance to EGFR tyrosine kinase inhibitors
L Huang, L Fu - Acta Pharmaceutica Sinica B, 2015 - Elsevier
… The importance of EGFR to lung cancers supports the concept of ‘oncogene addiction’.
Tyrosine kinase inhibitors (TKIs) have been used to treat the cancer harboring EGFR mutations …
Tyrosine kinase inhibitors (TKIs) have been used to treat the cancer harboring EGFR mutations …
Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
… In the updated result of BR.21, EGFR FISH + patients had significantly higher RR than FISH
- patients (21 vs 5%; p = 0.02). Moreover, survival benefit of erlotinib was seen in patients …
- patients (21 vs 5%; p = 0.02). Moreover, survival benefit of erlotinib was seen in patients …
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
BC Liao, CC Lin, JH Lee, JCH Yang - Lung Cancer, 2017 - Elsevier
… tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, and the second-generation
EGFR… -line treatments for advanced EGFR-mutant non-small cell lung cancer (NSCLC) based …
EGFR… -line treatments for advanced EGFR-mutant non-small cell lung cancer (NSCLC) based …
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
M Offin, H Rizvi, M Tenet, A Ni, F Sanchez-Vega… - Clinical Cancer …, 2019 - AACR
… EGFR exon19del or L858R-mutant lung cancers treated with first/second-generation EGFR
tyrosine kinase … EGFR wild-type lung adenocarcinoma samples were used for comparison. …
tyrosine kinase … EGFR wild-type lung adenocarcinoma samples were used for comparison. …
[HTML][HTML] EGFR targeted therapy in lung cancer; an evolving story
C Bartholomew, L Eastlake, P Dunn… - Respiratory medicine case …, 2017 - Elsevier
… Third generation EGFR TKIs, such as Osimertinib, are … -cell lung cancer who has undergone
EGFR targeted therapy and … be a sensitising mutation to EGFR tyrosine kinase inhibitors. …
EGFR targeted therapy and … be a sensitising mutation to EGFR tyrosine kinase inhibitors. …
[HTML][HTML] EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome
A Tiefenbacher, R Pirker - Journal of thoracic disease, 2017 - ncbi.nlm.nih.gov
… cancers than in those with non-oncogene-driven cancers. This … related cancers than in EGFR
mutation-positive driven cancers… EGFR mutation-positive NSCLC remains yet to be proven. …
mutation-positive driven cancers… EGFR mutation-positive NSCLC remains yet to be proven. …
Newer-generation EGFR inhibitors in lung cancer: how are they best used?
T Le, DE Gerber - Cancers, 2019 - mdpi.com
… (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung
cancer (NSCLC) with sensitizing EGFR … -naïve patients with EGFR mutant NSCLC, osimertinib …
cancer (NSCLC) with sensitizing EGFR … -naïve patients with EGFR mutant NSCLC, osimertinib …
Epidermal growth factor receptor tyrosine kinase inhibitor–resistant disease
… EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present
an update … This article reviews the clinical implications of EGFR mutations in lung cancer …
an update … This article reviews the clinical implications of EGFR mutations in lung cancer …
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
… (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR mutation-positive non-small
cell lung cancer (… patients with tumors harboring common EGFR mutations (exon 19 deletions […
cell lung cancer (… patients with tumors harboring common EGFR mutations (exon 19 deletions […
[HTML][HTML] … (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small …
Y Chen, S Wen, Y Wu, L Shi, X Xu, B Shen - Critical Reviews in Oncology …, 2021 - Elsevier
… Hence, we performed a systematic review and meta-analysis to provide an update and to
summarize the efficacy and safety of EGFR-TKIs combined with chemotherapy or …
summarize the efficacy and safety of EGFR-TKIs combined with chemotherapy or …